DeepMed Research

NEUROCRINE BIOSCIENCES, INC.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: Public

Established: 1992-01-01

Employees: 1.4K

Market Cap: $15.4B

Website: http://www.neurocrine.com

Clinical Trials

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase 2

Terminated

Conditions: Focal Onset Seizure
Focal Onset Epilepsy

Interventions: Drug: NBI-921352

First Posted Date: 2022-08-09

Last Posted Date: 2024-04-12

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 82

Registration Number: NCT05493293

Locations: 🇪🇸
Neurocrine Clinical Site, Valencia, Spain

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase 2

Terminated

Conditions: Epileptic Encephalopathy
Continuous Spike and Wave During Sleep

Interventions: Drug: NBI-827104

First Posted Date: 2022-03-31

Last Posted Date: 2025-02-28

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 19

Registration Number: NCT05301894

Locations: 🇬🇧
Neurocrine Clinical Site, London, United Kingdom

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Phase 2

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome

Interventions: Drug: NBI-921352

First Posted Date: 2022-02-07

Last Posted Date: 2024-05-22

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 52

Registration Number: NCT05226780

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 1 locations

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Phase 3

Recruiting

Conditions: Dyskinesia
Cerebral Palsy

Interventions: Drug: Placebo
Drug: Valbenazine

First Posted Date: 2022-01-25

Last Posted Date: 2025-04-02

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 80

Registration Number: NCT05206513

Locations: 🇪🇸
Neurocrine Clinical Site, San Sebastián, Spain
🇦🇷
Neurocrine Clincial Site, Ciudad Autónoma de Buenos Aires, Argentina

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: NBI-1065845

First Posted Date: 2022-01-24

Last Posted Date: 2025-01-15

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 183

Registration Number: NCT05203341

Locations: 🇸🇪
Neurocrine Clinical Site, Stockholm, Sweden

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: Luvadaxistat
Drug: Placebo

First Posted Date: 2022-01-10

Last Posted Date: 2024-12-24

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 216

Registration Number: NCT05182476

Locations: 🇪🇸
Neurocrine Clinical Site, Madrid, Spain

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

Phase 2

Completed

Conditions: Anhedonia
Major Depressive Disorder

Interventions: Drug: Placebo
Drug: NBI-1065846

First Posted Date: 2021-12-21

Last Posted Date: 2024-07-31

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 93

Registration Number: NCT05165394

Locations: 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase 2

Completed

Conditions: Focal Onset Seizure
Focal Onset Epilepsy

Interventions: Drug: Placebo
Drug: NBI-921352

First Posted Date: 2021-12-16

Last Posted Date: 2023-09-21

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 101

Registration Number: NCT05159908

Locations: 🇪🇸
Neurocrine Clinical Site, Valencia, Spain

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine As Adjunctive Treatment for Schizophrenia

Phase 3

Active, not recruiting

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Valbenazine

First Posted Date: 2021-11-05

Last Posted Date: 2024-12-24

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 442

Registration Number: NCT05110157

Locations: 🇷🇸
Neurocrine Clinical Site, Vršac, Serbia
🇺🇸
Neurocrine Clinical Sites, Glen Oaks, New York, United States
🇷🇸
Neurocrine Clinical Site 1, Kragujevac, Serbia

and more 5 locations

Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

Phase 2

Completed

Conditions: Essential Tremor

Interventions: Drug: NBI-827104
Drug: Placebo

First Posted Date: 2021-05-11

Last Posted Date: 2022-07-12

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 31

Registration Number: NCT04880616

Locations: 🇳🇱
Neurocrine Clinical Site, Leiden, CL, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy